Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$6.92 USD

6.92
33,829

+0.10 (1.47%)

Updated Oct 31, 2025 04:00 PM ET

After-Market: $6.94 +0.02 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

KMDA vs. NVZMY: Which Stock Is the Better Value Option?

by Zacks Equity Research

KMDA vs. NVZMY: Which Stock Is the Better Value Option?

Zacks Equity Research

Wall Street Analysts Believe Kamada (KMDA) Could Rally 113.15%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Kamada (KMDA) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Kamada (KMDA)

by Zacks Equity Research

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Are Investors Undervaluing Kamada (KMDA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

KMDA or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Does Kamada (KMDA) Have the Potential to Rally 114.39% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Kamada (KMDA) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Should Value Investors Buy Kamada (KMDA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Investors Undervaluing Kamada (KMDA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Wall Street Analysts See an 110.11% Upside in Kamada (KMDA): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 110.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

KMDA or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KMDA vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy Kamada (KMDA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

3 Reasons Growth Investors Will Love Kamada (KMDA)

by Zacks Equity Research

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

What Makes Kamada (KMDA) a New Buy Stock

by Zacks Equity Research

Kamada (KMDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

KMDA vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Investors Undervaluing Kamada (KMDA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Kamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Kamada (KMDA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Kamada (KMDA) Q2 Earnings Top Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of +44.44% and -0.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -13.95% and +124.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exploring Analyst Estimates for Kamada (KMDA) Q2 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Kamada (KMDA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Verastem (VSTM) delivered earnings and revenue surprises of +54.12% and -86.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KMDA or ACAD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KMDA vs. ACAD: Which Stock Is the Better Value Option?